Prognosis After Pacemaker Implantation in Alcohol Septal Ablation

One of the main complications of alcohol septal ablation (ASA) is the alteration in the conduction system, which could lead to permanent pacemaker (PPM) implantation. This is mainly due to the relationship between septal perfusion and the conduction system (especially the right bundle branch). The incidence reported in the literature is 7% to 20% of all cases.

Pronóstico post implante de marcapasos en ablación septal con alcohol

The aim of this research was to determine the short- and long-term endpoints of patients who required PPM implantation for high-grade atrioventricular block after ASA. Data from the multinational Euro-ASA Registry were analyzed.

Patients with PPM were studied and propensity score matching was conducted to group them and compare them with subjects without device implantation.

The endpoints analyzed were 30-day all-cause mortality, all-cause mortality at the long-term follow-up, long-term functional class, long-term outflow tract gradient, and reintervention rate. The mean follow-up was 4.9 years.

The PPM implantation rate was 9.4% at 30 days and there was an additional 3.1% at follow-up. The pooled cohort comprised 278 patients; 139 in the PPM arm and 139 in the non-PPM arm. Mortality at 30 days was 0.4%, with no significant differences between groups. Patients with PPM generally presented previous bundle branch block (= 0.01), were treated with a higher dose of alcohol (p = 0.03), and had a more marked gradient reduction (p ≤ 0.01).

Read also: Is Right Ventricle-Pulmonary Artery (RV-PA) Coupling Important in Low Risk TAVR?

The multivariate analysis identified age and the presence of previous bundle branch block as predictors of all-cause mortality.

The baseline predictors of PPM implantation were higher age range, worse functional class, higher alcohol dose, and the presence of previous block.

Conclusion

In the Euro-ASA Registry, PPM implantation did not lead to higher mortality. Considering that these are data obtained from a large registry, the sample of 278 patients was limited, which is an important hypothesis generator.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...